The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab

Ann Oncol. 2010 Dec;21(12):2447-2448. doi: 10.1093/annonc/mdq640. Epub 2010 Oct 28.

Authors

L H J Simkens¹, J Tol¹, L W M M Terstappen², S Teerenstra³, C J A Punt¹, I D Nagtegaal⁴

Affiliations

¹ Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen.
² Department of Medical Cell Biophysics, Faculty of Sciences and Technology, Twente University, Enschede.
³ Department of Epidemiology, Biostatistics, and Health Technology Assessment.
⁴ Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: i.nagtegaal@pathol.umcn.nl.

PMID: 21030382
DOI: 10.1093/annonc/mdq640

No abstract available

Publication types

Evaluation Study
Letter
Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Biomarkers, Tumor / blood*
Carcinoma / blood
Carcinoma / diagnosis*
Carcinoma / drug therapy*
Clinical Trials, Phase III as Topic
Colorectal Neoplasms / blood
Colorectal Neoplasms / diagnosis*
Colorectal Neoplasms / drug therapy*
Diagnostic Techniques and Procedures
Disease Progression
Endothelial Cells / pathology*
Humans
Neoadjuvant Therapy
Neoplastic Cells, Circulating / pathology
Predictive Value of Tests
Prognosis
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
Bevacizumab